About this trial
This project aims to evaluate the safety and efficacy of precision genetic therapy for patients with Ataxia-telangiectasia (A-T), a rare neurodegenerative disease caused by mutations in the ATM gene. The investigators will conduct a clinical trial to study the safety and efficacy of intrathecal administration of atipeksen, a targeted genetic therapy that restores ATM gene function in A-T individuals bearing the recurrent ATM c.7865C\>T variant. The aim of this study is to delay or forestall progression of neurologic symptoms in A-T and improving quality of life. Success will provide an empirical foundation for advancing additional precision genetic therapies for A-T and other neurodegenerative conditions.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
People with classic A-T confirmed by genetic testing
Must have a specific ATM gene change (c.7865C>T)
Must also have another ATM change that causes A-T
Blood clotting or bleeding problems
Trial design
Single group
Treatments tested in this trial
Antisense oligonucleotide targeting the ATM gene
DrugAtipeksen is a fully modified PS-2'MOE splice-switching antisense oligonucleotide that is designed to restore normal splicing patterns in patients with the ATM c.7865C\>T mutation.
Treatment groups
Trial outcomes
Primary outcomes
Neurological function as measured by the AT-NEST scale
The Ataxia-Telangiectasia Neurological Examination Toolkit (AT-NEST) is a test designed specifically for people with Ataxia-Telangiectasia (A-T). It helps doctors and researchers understand how the brain and nerves are working. The test looks at six main areas: * Communication * Eye movements Ataxia (problems with balance and coordination) * Movement disorders * Muscle strength (Power) * Nerve function (Neuropathy) These six areas make up the "pure neuro" score, which ranges from 0 (lowest) to 100 (highest). The test also includes growth and nutrition. When these are added to the six main areas, a total "neuro-related" score is calculated, with a maximum of 114. Higher scores mean better overall performance.This test is not painful and is carried out by trained specialists who will guide you through each step.
Ataxia-Telangiectasia Structured Clinical Global Impression of Change (A-T CGI)
The Ataxia-Telangiectasia Clinical Global Impression of Change (AT-CGI) is a tool used to track how A-T progresses over time. It looks at five main areas of the disease: Ataxia (balance and coordination problems) Dysarthria (difficulty speaking) Repetitive movements / Dysmetria (trouble controlling movements) Movement disorders Eye movements Each area is scored from 0 to 4, for a total of 20 points. Higher scores mean more severe symptoms, while lower scores indicate better function.
Secondary outcomes
Motor performance as measured by the Bruininks-Oseretsky Test of Motor Proficiency 2nd edition
The Bruininks-Oseretsky Test of Motor Proficiency 2nd edition (BOT-2) is a simple way for therapists to check how your child is developing movement skills. It looks at: * Small hand and finger movements (fine motor) * How quickly and accurately hands are used (dexterity) * Big movements like running or jumping (gross motor) * How well the body works together (coordination) During the test, the child does different activities, and each one is scored. These scores are added up to give both an overall score (out of 200 points) and separate scores for each skill area. The results are then compared to what is typical for children of the same age.
Performance and goal satisfaction as measured by the Canadian Occupational Performance Measure (COPM)
The Canadian Occupational Performance Measure (COPM) is a test done by an occupational therapist to understand what daily activities are most important to a person and how well they feel they can do them. During the test, the person picks up to five activities they find difficult or want to improve. For each activity, they rate: * How well they can do it * How satisfied they are with their performance Both scores range from 1 to 10 (higher numbers mean better performance or more satisfaction). The scores are then averaged to see overall progress. The main goal is to track improvements over time, especially before and after a therapy or intervention.
Performance in activities of daily living as measured by the Pediatric Evaluation of Disability Inventory Computer Adaptive Test
The Pediatric Evaluation of Disability Inventory - Computer Adaptive Test (PEDI-CAT) is a questionnaire filled out by parents or caregivers. It helps us understand how a child is doing in everyday life. It looks at four areas: * Daily activities (like eating, dressing, and personal care) * Mobility (how a child moves around) * Social/cognitive (how a child plays, communicates, and learns) * Responsibility (how much a child can manage tasks at home or in the community) The test is "adaptive," meaning the questions change depending on how you answer, so it fits your child's abilities. Each area gets a score from 0 to 100, with higher scores meaning better functional ability.
Visual-motor function as measured by the Beery-Buktenica Developmental Test of Visual Motor Integration
The Beery-Buktenica Developmental Test of Visual-Motor Integration (Beery-VMI) is a test often given by occupational therapists to see how well a child's eyes and hands work together. During the test, the child copies shapes and designs that get harder as the test goes on. Sometimes the child may also be asked to find differences between pictures or match patterns. The results show: * A standard score with a range of 45 to 155; higher scores indicate a better performance * A percentile score, which shows what percentage of children the same age scored lower. This helps parents and therapists see how the child's coordination and fine motor skills are compared to others their age.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Timothy Yu
Lead sponsor
Boston Children's Hospital
Sponsor institution